Metabolic Reprogramming and Tumor Microenvironment: Emerging Mechanisms of Cancer Development and Therapeutic Resistance

Cancer progression is driven by complex interactions between metabolic reprogramming, mitochondrial dysfunction, and the tumor microenvironment (TME). Cancer cells undergo profound metabolic adaptations that enable them to sustain rapid proliferation, maintain redox balance, and survive under conditions of hypoxia, nutrient deprivation, and cellular stress. Although aerobic glycolysis is a recognized feature of many tumors, mitochondrial oxidative phosphorylation (OXPHOS) remains essential in numerous cancer types, contributing to ATP production, biosynthetic pathways, and metabolic flexibility. These complementary energy-generating mechanisms allow malignant cells to adapt to changing microenvironmental conditions and maintain tumor growth.The tumor microenvironment further shapes cancer metabolism through interactions among malignant cells, cancer-associated fibroblasts, immune cells, endothelial cells, and extracellular matrix components. Hypoxia-inducible signaling, nutrient competition, lactate accumulation, and altered lipid and amino acid metabolism can promote angiogenesis, immune evasion, invasion, and metastatic dissemination. In addition, metabolic communication between tumor cells and surrounding stromal cells can influence mitochondrial activity, inflammatory signaling, and resistance to anticancer treatments. These interactions create a dynamic ecosystem in which metabolic adaptation and microenvironmental signaling reinforce tumor survival and progression. Mitochondrial reactive oxygen species (ROS) and redox-regulatory pathways contribute to this process by acting as signaling mediators that influence genomic stability, cellular proliferation, apoptosis, and therapeutic responses. Cancer cells may also modify mitochondrial dynamics, mitophagy, and antioxidant defenses to preserve cellular fitness under stress. Meanwhile, metabolic alterations within the TME can impair antitumor immune responses and support the persistence of treatment-resistant cancer cell populations. Understanding the relationship between mitochondrial function, metabolic plasticity, and microenvironmental regulation is therefore essential for identifying the mechanisms underlying cancer progression and therapeutic resistance.Emerging technologies, including single-cell transcriptomics, spatial multi-omics, metabolomics, and advanced mitochondrial profiling, provide opportunities to characterize metabolic heterogeneity across tumor regions and cellular populations. Integrating these approaches can reveal how specific metabolic states are associated with tumor evolution, immune suppression, metastatic potential, and treatment response. Ultimately, identifying the metabolic dependencies and signaling pathways that connect cancer cells with their microenvironment may support the development of targeted therapeutic strategies, improve patient stratification, and provide new opportunities to overcome resistance to conventional cancer treatments.